Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv, Sanofi SafiledCriticalAblynx Nv
Publication of AR120694A1publicationCriticalpatent/AR120694A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Peptides Or Proteins
(AREA)
Abstract
La presente tecnología tiene como objetivo proporcionar un tipo de fármaco para tratar a un sujeto que padece una enfermedad autoinmunitaria o una enfermedad inflamatoria. Específicamente, la presente tecnología proporciona polipéptidos que comprenden al menos cuatro dominios variables únicos de inmunoglobulina (ISVD), caracterizados por que al menos dos ISVD se unen a TNFa y al menos dos ISVD se unen a OX40L. La presente tecnología también proporciona ácidos nucleicos, vectores y composiciones.The present technology aims to provide a type of drug for treating a subject suffering from an autoimmune disease or an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind TNFa and at least two ISVDs bind OX40L. The present technology also provides nucleic acids, vectors, and compositions.
ARP200103412A2019-12-062020-12-09
POLYPEPTIDES COMPRISING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULIN TARGETING TNFa AND OX40L
AR120694A1
(en)
canine crystallizable fragment region, antibody, nucleic acid, expression vector, host cell, pharmaceutical composition, and method for enhancing the activity of an immune cell